Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SiPc + biotin refers to a chemically conjugated compound consisting of **silicon phthalocyanine** (SiPc), a **photosensitizer** molecule, linked to **biotin** for targeted biomedical applications. Silicon phthalocyanine functions as a photosensitizer used in photodynamic therapy, generating reactive oxygen species upon light activation, which can damage or kill targeted cells. Biotin is used in this formulation as a targeting ligand, exploiting its high affinity for biotin receptors (often overexpressed in certain cancer cells), thereby enhancing selective delivery of the photosensitizer to tumor tissues. The conjugation is designed to improve tumor selectivity and photodynamic therapeutic efficacy compared to SiPc alone. This is a research formulation and not an approved pharmaceutical product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SiPc + biotin.